Index by author

December 01, 2010; Volume 77,Issue 12

  1. Malone, Donald

    1. MAO inhibitors: Risks, benefits, and lore
      Molly Wimbiscus, MD, Olga Kostenko, MD and Donald Malone, MD
      Cleveland Clinic Journal of Medicine December 2010, 77 (12) 859-882; DOI: https://doi.org/10.3949/ccjm.77a.09103

      Monoamine oxidase inhibitors were the first antidepressants introduced. Interest in their use is reviving.

  2. Mandell, Brian F.

    1. Why is fixing the plumbing so difficult?
      Brian F. Mandell, MD, PhD
      Cleveland Clinic Journal of Medicine December 2010, 77 (12) 840; DOI: https://doi.org/10.3949/ccjm.77b.10012

      For carotid stenosis, a catheter-based procedure would seem safer than endarterectomy, but reality is not always so simple.

    2. Managing gout: How is it different in patients with chronic kidney disease?
      Hossam El-Zawawy, MD, MS and Brian F. Mandell, MD, PhD
      Cleveland Clinic Journal of Medicine December 2010, 77 (12) 919-928; DOI: https://doi.org/10.3949/ccjm.77a.09080

      The goals are the same, but the choice and dosage of drugs may need to be modified.

  3. Manson, Joann E.

    1. Vitamin D and the heart: Why we need large-scale clinical trials
      Joann E. Manson, MD, DrPH, FAHA
      Cleveland Clinic Journal of Medicine December 2010, 77 (12) 903-910; DOI: https://doi.org/10.3949/ccjm.77gr.10004

      Despite enthusiasm for vitamin D, no large-scale primary prevention trial has used cardiovascular disease or cancer as a prespecified primary outcome.

  4. Messerli, Franz H.

    1. Should alpha-blockers ever be used as antihypertensive drugs?
      Giacomo Rossitto, MD, Ganesh Kamath, MD and Franz H. Messerli, MD
      Cleveland Clinic Journal of Medicine December 2010, 77 (12) 884-888; DOI: https://doi.org/10.3949/ccjm.77a.10058

      They are not first-line drugs, but they can be second-line or third-line add-on drugs if blood pressure is not under control.

Back to top

In this issue